Publications

  1. Stewart MW. Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep. 2014 Aug; 14(8):510.
    View PubMed
  2. Moore SA, Rabinstein AA, Stewart MW, David Freeman W. Recognizing the signs and symptoms of aneurysmal subarachnoid hemorrhage. Expert Rev Neurother. 2014 Jul; 14(7):757-68.
    View PubMed
  3. Schwartz SG, Scott IU, Flynn HW Jr, Stewart MW. Drug delivery techniques for treating age-related macular degeneration. Expert Opin Drug Deliv. 2014 Jan; 11(1):61-8. Epub 2013 Nov 13
    View PubMed
  4. Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Exp Rev Clin Pharmacol. 2014; 7(2):167-80.
  5. Maturi RK, Chen V, Raghinaru D, Bleau L, Stewart MW. A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion. Clin Ophthalmol. 2014; 8:1057-64. Epub 2014 Jun 03.
    View PubMed
  6. Kaiser PK, Brown DM, Kitchens JW, MacCumber MW, Singh RP, Stewart MW. The impact of anti-VEGF treatments on naïve AMD patients. How to choose an agent Part 1 Retinal Physician. 2014; June Suppl:1-17.
  7. Stewart MW. Clinically relevant pharmacology of anti-VEGF agents. Intravitreal Interventions. 2014; 3(1):1, 4-6.
  8. Stewart MW. Review of the latest treatments for retinal vein occlusions: emphasis on pharmacologic therapy. Exp Review Ophthalmol. 2014. [Epub ahead of print]
  9. Smith CD, Spackman T, Brommer K, Stewart MW, Vizzini M, Frye J, Rupp WC. Re-engineering the operating room using variability methodology to improve health care value. J Am Coll Surg. 2013 Apr; 216(4):559-68; discussion 568-70.
    View PubMed
  10. Stewart MW. Herpetic (non-cytomegalovirus) retinal infections in patients with the acquired immunodeficiency syndrome. Curr HIV Res. 2013 Apr; 11(3):210-9.
    View PubMed
  11. Stewart MW. Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration. Expert Rev Clin Pharmacol. 2013 Mar; 6(2):103-13.
    View PubMed
  12. Stewart MW. PDGF: ophthalmology’s next great target. Exp Rev Ophthalmol. 2013; 8(6):527-537.
  13. Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. Ocular Times. 2013.
  14. Stewart MW. Review of aflibercept for the treatment of neovascular age-related macular degeneration. Clinical Medicine Insights: Therapeutics. 2013; 5:81-93.
  15. Stewart MW. Aflibercept as a treatment for age-related macular degeneration. US Ophthalmic Reviews. 2013; 6(1):58-63.
  16. Stewart MW. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol. 2013; 7:1257-67. Epub 2013 Jun 24.
    View PubMed
  17. Stewart MW. One-year results of intravitreal ranibizumab 0.5 mg vs 20 mg for the treatment of exudative age-related macular degeneration. Expert Rev Ophthalmol. 2013; 8(4):341-345.
  18. Stewart MW. Aflibercept Ophthalmic Solution: Drug development and clinical uses. Clinical Investigation. 2013; 3(11):1045-56.
  19. Stewart MW. Aflibercept in the treatment of wet macular degeneration. J Signs Symptoms. 2013; 2(4):203-212.
  20. Stewart MW. 1-year results of intravitreal aflibercept treatment for macular edema due to central retinal vein occlusion. Expert Rev. Ophthalmol. 2013; 8(3):241-4.
  21. Stewart MW, Stewart ML. Topical azithromycin or ofloxacin for endophthalmitis. Clin Ophthalmol. 2013; 7:35-6. Epub 2012 Dec 31
    View PubMed
  22. Forlenza GP, Stewart MW. Diabetic retinopathy in children. Pediatr Endocrinol Rev. 2012 Dec-2013 Jan; 10(2):217-26.
    View PubMed
  23. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012 Aug; 154(2):222-6.
    View PubMed
  24. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012 Aug; 12(4):364-75.
    View PubMed
  25. Stewart MW. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr Diabetes Rev. 2012 Jul 1; 8(4):237-46.
    View PubMed
  26. Butendieck RR, Parikh K, Stewart M, Davidge-Pitts C, Abril A. Systemic lupus erythematosus-associated retinal vasculitis. J Rheumatol. 2012 May; 39(5):1095-6.
    View PubMed
  27. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012 Mar; 32(3):434-57.
    View PubMed
  28. Gonzalez S, Rosenfeld PJ, Stewart MW, Brown J, Murphy SP. Avastin doesn't blind people, people blind people. Am J Ophthalmol. 2012 Feb; 153(2):196-203.e1.
    View PubMed
  29. Stewart MW. Human immunodeficiency virus and its effects on the visual system. Infect Dis Rep. 2012 Jan 2; 4(1):e25. Epub 2012 Mar 08.
    View PubMed
  30. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012 Jan; 87(1):77-88.
    View PubMed
  31. Stewart MW. Vascular endothelial growth factor (VEGF) biochemistry and development of inhibitory drugs. Current Drug Therapy. 2012; 7(2):80-9.
  32. Stewart MW. Vascular endothelial growth factor inhibitor use in ophthalmology: The revolution continues. Current Drug Therapy. 2012; 7(2):77-9.
  33. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012; 6:1175-86. Epub 2012 Jul 26.
    View PubMed
  34. Stewart MW. Pharmacokinetics of intravitreal anti-VEGF agents: practical clinical implications. Intervitreal Interventions. 2012; 1(1):1-4.
  35. Vanner EA, Stewart MW, Liesegang TJ, Bendel RE, Bolling JP, Hasan SA. A retrospective cohort study of clinical outcomes for intravitreal crystalline retained lens fragments after age-related cataract surgery: a comparison of same-day versus delayed vitrectomy. Clin Ophthalmol. 2012; 6:1135-48. Epub 2012 Jul 18.
    View PubMed
  36. Stewart MW. New anti-VEGF antibody therapies in Ophthalmology. Curr Med Literature - Ophthalmology. 2012; 22(4):105-113.
  37. Stewart MW. Early experience using aflibercept in the treatment of wet macular degeneration. Intravitreal Interventions. 2012; 1(4):1-11.
  38. Stewart MW. Unilateral vision loss following contralateral eye treatment. Intravitreal Interventions. 2012; 1(2):13.
  39. Stewart MW. Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets. 2011 Dec; 10(6):497-508.
    View PubMed
  40. Davis J, Olsen TW, Stewart M, Sternberg P Jr. How the comparison of age-related macular degeneration treatments trial results will impact clinical care. Am J Ophthalmol. 2011 Oct; 152(4):509-14.
    View PubMed
  41. Vanner EA, Stewart MW. Vitrectomy timing for retained lens fragments after surgery for age-related cataracts: a systematic review and meta-analysis. Am J Ophthalmol. 2011 Sep; 152(3):345-357.e3. Epub 2011 Jun 17.
    View PubMed
  42. Stewart MW. Impact of HIV on vision. Northeast Florida Medicine. 2011; 62(2):3-8.
  43. Stewart MW, Vavra MW, Whaley NR. Fundus findings in a patient with [alpha]-methylacyl-CoA racemase deficiency. Retinal Cases and Brief Reports. 2011; 5(3):262-266.
  44. Stewart MW. What are the half-lives of ranibizumab, aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Reports. 2011; 1(1):12-14.
  45. Stewart MW. Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin Ophthalmol. 2010; 4:285-99. Epub 2010 Apr 26.
    View PubMed
  46. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008 May; 92(5):667-8. Epub 2008 Mar 20.
    View PubMed
  47. Stewart MW. Predicted biologic activity of intravitreal bevacizumab. Retina. 2007 Nov-Dec; 27(9):1196-200.
    View PubMed
  48. Shetty RK, Boilling JP, Stewart MW, Heckman MG. Differences in optical coherence tomography of the macula in advanced glaucoma and after a retinal artery occlusion. Ophthalmic Surg Lasers Imaging. 2007 Sep-Oct; 38(5):392-8.
    View PubMed
  49. Stewart MW, Brazis PW, Guier CP, Thota SH, Wilson SD. Purtscher-like retinopathy in a patient with HELLP syndrome. Am J Ophthalmol. 2007 May; 143(5):886-7.
    View PubMed
  50. Hasan SA, Stewart MW. Cystoid macular edema following photorefractive keratectomy complicated by presumptive infectious keratitis. J Cataract Refract Surg. 2007 Feb; 33(2):348-9.
    View PubMed
  51. Stewart MW. Intravitreal bevacizumab (avastin) for the treatment of chorioretinal vascular diseases. Techniques in Ophthalmology. 2007; 5(1):40-5.
    View PubMed
  52. Stewart MW, Alvarez S, Ginsburg WW, Shetty R, McLain WC, Sleater JP. Visual recovery following Mycobacterium chelonae endophthalmitis. Ocul Immunol Inflamm. 2006 Jun; 14(3):181-3.
    View PubMed
  53. Hellinger WC, Hasan SA, Bacalis LP, Thornblom DM, Beckmann SC, Blackmore C, Forster TS, Tirey JF, Ross MJ, Nilson CD, Mamalis N, Crook JE, Bendel RE, Shetty R, Stewart MW, Bolling JP, Edelhauser HF. Outbreak of toxic anterior segment syndrome following cataract surgery associated with impurities in autoclave steam moisture. Infect Control Hosp Epidemiol. 2006 Mar; 27(3):294-8. Epub 2006 Feb 22.
    View PubMed
  54. Stewart MW, Landers MB 3rd. Transscleral intraocular lens fixation with a "homemade" needle and hook. J Cataract Refract Surg. 2006 Feb; 32(2):200-2.
    View PubMed
  55. Stewart MW, Liesegang TJ, Schwam BL. Chlamydia conjunctivitis and central retinal vein occlusion. Am J Ophthalmol. 2005 Jul; 140(1):161-2.
    View PubMed
  56. Stewart MW. Intraoperative radiographic detection of a "lost" scleral plug. Retina. 2005 Jun; 25(4):526-7.
    View PubMed
  57. Stewart MW, Brazis PW, Barrett KM, Eidelman BH, Mendez JC. Optical coherence tomography in a case of bilateral neuroretinitis. J Neuroophthalmol. 2005 Jun; 25(2):131-3.
    View PubMed
  58. Stewart MW, Bolling JP, Mendez JC. Cytomegalovirus retinitis in an immunocompetent patient. Arch Ophthalmol. 2005 Apr; 123(4):572-4.
    View PubMed
  59. Stewart MW. Treatment of an avulsed retinal vessel with infrared diode laser photocoagulation. Am J Ophthalmol. 2004 Apr; 137(4):767-8.
    View PubMed
  60. Brazis PW, Stewart M, Lee AG. The uveo-meningeal syndromes. Neurologist. 2004; 10(4):171-84.
    View PubMed
  61. Brazis PW, Lee AG, Stewart M, Capobianco D. Clinical review: The differential diagnosis of pain in the quiet eye. Neurologist. 2002; 8(2):82-100.
    View PubMed
  62. Stewart MW. Choroidal melanoma. Jacksonville Medicine. 2000; 51:393-399.
  63. Stewart MW, Lambrou FH Jr. AIDS Retinopathy. Jacksonville Medicine. 1997; 48:347-51.
  64. Stewart MW, Lambrou FH Jr, Watson M. Intravitreal ganciclovir injections for the treatment of cytomegalovirus retinitis. Ophthalmology. 1997; 104(Suppl):S149.
    View PubMed
  65. Skowsky WR, Siddiqui T, Hodgetts D, Lambrou FH, Stewart MW, Foster MT Jr. A pilot study of chronic recombinant interferon-alfa 2a for diabetic proliferative retinopathy: metabolic effects and ophthalmologic effects. J Diabetes Complications. 1996; 10(2):94-9.
    View PubMed
  66. Stewart MW. Update on CMV retinitis. Review of Ophthalmol. 1994 Nov:5-52.
  67. Pogrebniak AE, Bolling JP, Stewart MW. Argon laser-induced cataract in an infant with retinopathy of prematurity. Am J Ophthalmol. 1994 Feb 15; 117(2):261-2.
    View PubMed
  68. Friedman SM, Mames RN, Stewart MW. Subretinal hemorrhage after grid laser photocoagulation for idiopathic juxtafovealar retinal telangiectasis. Ophthalmol Surg. 1993; 24:551-3.
  69. Lambrou FH Jr, Stewart MW. Management of dislocated lens fragments during phacoemulsification. Ophthalmology. 1992 Aug; 99(8):1260-2; discussion 1268-9.
    View PubMed
  70. Stewart MW, Lambrou FH Jr. Management of dislocated lens fragments: Pars plana vitrectomy and transscleral fixation of posterior chamber lens implants. Vitreoretinal Surg and Tech. 1992; 4(3):5-6.
  71. Hjelmeland LM, Stewart MW, Li J, Toth CA, Burns MS, Landers MB III. An experimental model of ectropion uveae and iris neovascularization in the cat. Invest Ophthalmol Vis Sci. 1992; 33(5):1796-803.
    View PubMed
  72. Landers MBL III, Stewart MW, Maberely D, Serdahl C. A new inexpensive pump for vitreoretinal surgery. Arch Ophthalmol. 1991; 109:142-3.
    View PubMed
  73. Arora N, Lambrou FH Jr, Stewart MW, et al. Sudden blindness associated with central nervous symptoms in a hemodialysis patient. Nephron. 1991; 59:490-2.
    View PubMed
  74. Lambrou FH, Stewart MW. Management of dislocated lens fragments. Ophthalmol. 1991; 98(Suppl 8):169.
  75. Sternberg P Jr, Meredith TA, Stewart MW, Kaplan HJ. Retinal detachment in penetrating keratoplasty patients. Am J Ophthalmol. 1990; 109:148-52.
    View PubMed
  76. Stewart MW, Lambrou FH Jr. Lasers and retina surgery. Jacksonville Medicine. 1990; 41:448-50.
  77. Stewart MW, Gitter KA, Cohen G. Acute leukemia presenting as a unilateral exudative retinal detachment. Retina. 1989; 9:110-4.
    View PubMed
  78. Gitter KA, Stewart MW, She SC, Paulus P, Cohen G. Practical management of diabetic retinopathy. J La State Med Soc. 1988 Oct; 140(10):26-38.
    View PubMed
  79. Stewart MW, Gitter KA. Inherited retinal venous beading. Am J Ophthalmol. 1988; 106:675-81.
    View PubMed